alexa Abstract | Case Reports: Aripripazole Reduces Risperidone-Induced Hyperprolactinemia

Biomedical Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Many schizophrenic patients treated with typical or atypical antipsychotics (AP) such as risperidone show significant clinical alterations as changes in sexual activity, menstrual cycle, amenorrhea, galattorrea and cardiovascular disorders because of AP-induced hyperprolactinemia. In the present paper we report two clinical cases showing, after switching with aripiprazole, a PRL normalization and a marked improvement of clinical events related to risperidone- induced hyperprolactinemia

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Walter Milano Luca Milano Claudio Petrella Andrea Ingenito Anna Capasso


Aripiprazole, Hyperprolactinemia, Risperidone

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version